Evidence of sunitinib-associated cardiotoxicity has emerged in a study of 75 patients with imatinib-resistant metastatic gastrointestinal stromal tumours (Lancet 2007;370:2011). Researchers in the US reviewed all cardiovascular events in these patients who had been enrolled in a phase I/II trial and treated with sunitinib (Sutent).The endpoints were cardiac death, myocardial infarction and congestive heart failure. The effects of sunitinib on left ventricular ejection fraction and blood pressure were also measured. Median follow up was 33.5 weeks.
展开▼
